Aims Worldwide observational studies are evidencing discordance between guidelines and
real‐world practice regarding direct oral anticoagulant drug (DOAC) doses. This systematic …

Background Recent reports suggest an important contribution from frequent off-label use of
apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in …

Atrial fibrillation (AF) and renal insufficiency often coexist and are increasingly prevalent with
advancing age. Both the risk of thromboembolic events and bleeding propensity are higher …

Direct oral anticoagulants (DOACs) have become the cornerstone for prevention of
thromboembolic events in patients with atrial fibrillation and patients with a history of venous …

Background Direct oral anticoagulants (DOACs) have complex dosing regimens and are
often incorrectly prescribed. We evaluated a nationwide DOAC population management …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are prescribed to
patients with atrial fibrillation (AF) to reduce the risk of stroke. Prescribing the correct dose …

Background Although several meta‐analyses have examined the effects of off‐label
underdosing of nonvitamin K antagonist oral anticoagulants (NOACs) compared with their …

In real-world clinical practice, underdosing, ie off-label use of reduced doses (RDs), of oral
factor Xa inhibitors (oFXaIs) is quite common in stroke prevention in non-valvular atrial …

Abstract Backgound Atrial Fibrillation (AF) is the most prevalent cardiac arrhythmia among
older patients, associated with thromboembolic events. Direct Oral Anticoagulants (DOAC) …

Introduction: Anticoagulants are associated with significant harm when used in error, but
there are limited data on potential harm of inappropriate treatment with direct oral …